Skip to main content
SpringerLink
Log in

Lung Cancer in the Elderly

Current and Future Chemotherapeutic Options

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Lung cancer is a prevalent malignancy disproportionately affecting the elderly, and in our aging societies will only increase in magnitude. Physicians typically assume that elderly lung cancer patients will have poorer prognoses. This belief is in part based on certain physiological changes of aging affecting the kidneys, liver, and bone marrow. However, there are no data to clearly support or refute increased toxicity from chemotherapy or a lessened therapeutic effect in the elderly based on these changes, although it is a field worthy of further study. Retrospective studies of treatment of elderly non-small cell and small cell lung cancer patients do not suggest a worse prognosis based on advanced age alone.

Clinicians are hampered by the lack of clinical trials focusing on or even including the elderly, despite the increased incidence of lung cancer in the elderly. Phase II studies in elderly non-small cell lung cancer patients concentrate on newer agents (vinorelbine and gemcitabine) alone or combined with platinum compounds in hopes of more favourable toxicity profiles. Phase III trials have demonstrated survival benefits, quality of life improvements, and acceptable toxicity profiles for vinorelbine compared to best supportive care alone and the combination of vinorelbine and gemcitabine compared to vinorelbine alone.

Data are also sparse for elderly small cell lung cancer patients. Phase II studies focused on single agent oral etoposide also in hopes of lessening toxicity. However, phase III trials have shown improvement in survival and quality of life for multiagent intravenous chemotherapy compared to oral etoposide.

Given the existing data, altering therapy for lung cancer patients based on age alone would not be warranted. Given the prevalence of the disease, future studies need to include an appropriate number of elderly patients with continued emphasis on quality of life in addition to survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49(1): 8–31, 1

    Article  PubMed  CAS  Google Scholar 

  2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80(7): 1273–83

    Article  PubMed  CAS  Google Scholar 

  3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

    Article  PubMed  CAS  Google Scholar 

  4. Hrushesky WJ, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76(4): 579–84

    Article  PubMed  CAS  Google Scholar 

  5. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12(10): 2121–5

    PubMed  CAS  Google Scholar 

  6. Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin for elderly patients. Age Ageing 1992; 21(3): 202–4

    Article  PubMed  CAS  Google Scholar 

  7. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function [see comments]. J Clin Oncol 1989; 7(11): 1748–56

    PubMed  CAS  Google Scholar 

  8. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61(3): 331–9

    Article  PubMed  CAS  Google Scholar 

  9. Cohen HJ. Geriatric principles of treatment applied to medical oncology: an overview. Semin Oncol 1995; 221 Suppl. 1: 1–2

    PubMed  CAS  Google Scholar 

  10. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic dysregulation?. [editorial; comment]. Blood 1993; 82(9): 2601–4

    PubMed  CAS  Google Scholar 

  11. Lipschitz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995; 221 Suppl. 1: 3–5

    PubMed  CAS  Google Scholar 

  12. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52(11): 1986–92

    Article  PubMed  CAS  Google Scholar 

  13. Langer C, Manola J, Bernardo P, et al. Advanced age alone does NOT compromise outcome in fit Non-Small Cell Lung Cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (TX): implications of ECOG 5592. Proceedings of the American Society of Clinical Oncology 2000; 19: 489a

    Google Scholar 

  14. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91(5): 710–7

    Google Scholar 

  15. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983; 43(9): 4467–9

    PubMed  CAS  Google Scholar 

  16. Nerenz DR, Love RR, Leventhal H, et al. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res 1986; 20 (6 Pt 2): 961–76

    PubMed  CAS  Google Scholar 

  17. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 747 Suppl.: 2208–14

    Article  PubMed  CAS  Google Scholar 

  18. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341(27): 2061–7

    Article  PubMed  CAS  Google Scholar 

  19. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4(5): 702–9

    PubMed  CAS  Google Scholar 

  20. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced Non-Small Cell Lung Cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992. Proceedings of the American Society of Clinical Oncology 1998; 17: 461a

    Google Scholar 

  21. Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 1999; 261 Suppl. 4: 3–11

    PubMed  CAS  Google Scholar 

  22. Vogl SE, Berenzweig M, Camacho F, et al. Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 1982; 50(1): 24–6

    Article  PubMed  CAS  Google Scholar 

  23. Samson MK, Comis RL, Baker LH, et al. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 1978; 62(1): 163–5

    PubMed  CAS  Google Scholar 

  24. Furnas BE, Williams SD, Einhorn LH, et al. Vindesine: an effective agent in the treatment of non-small cell lung cancer. Cancer Treat Rep 1982; 66(9): 1709–11

    PubMed  CAS  Google Scholar 

  25. Harrison EF, Hawke JE, Hunter HL, et al. Single-dose ifosfamide: efficacy studies in non-small cell lung cancer. Semin Oncol 1982; 94 Suppl. 1: 56–60

    PubMed  CAS  Google Scholar 

  26. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7(11): 1602–13

    PubMed  CAS  Google Scholar 

  27. Veronesi A, Crivellari D, Magri MD, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996; 32A(10): 1809–11

    Article  PubMed  CAS  Google Scholar 

  28. Colleoni M, Gaion F, Nelli P, et al. Weekly vinorelbine in elderly patients with non-small-cell lung cancer. Tumori 1994; 80(6): 448–52

    PubMed  CAS  Google Scholar 

  29. Shepherd FA, Abratt RP, Anderson H, et al. Gemcitabine in the treatment of elderly patients with advanced non- small cell lung cancer. Semin Oncol 1997; 242 Suppl. 7: S7–50–S7–55

    PubMed  CAS  Google Scholar 

  30. Martins SJ, Pereira JR, Ikari FK, et al. Chemotherapy (CT) with Cisplatin and Vinorelbine for elderly Non-Small Cell Lung Cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 1999; 18: 468a

    Google Scholar 

  31. Rosvold E, Langer C, McAleer C, et al. Advancing age does not exacerbate toxicity or compromise outcome in Non-Small Cell Lung Cancer (NSCLC) patients (pts) receiving Paclitaxel-Carboplatin (P-C). Program/Proceedings of the American Society of Oncology 1999; 18: 478a

    Google Scholar 

  32. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non- small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40(6): 469–74

    Article  PubMed  CAS  Google Scholar 

  33. Nguyen B, Sandler A, Denham C. The safety and efficacy of Gemcitabine plus Cisplatin in the elderly chemonaive NSCLC patients (age>70 years) as compared to those with age<70 years. Proceedings of the American Society of Clinical Oncology 1999; 18: 471a

    Google Scholar 

  34. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91(1): 66–72

    Article  Google Scholar 

  35. Frasci G, Lorusso V, Panza N, et al. Gemcitabine +Vinorelbine (GV) yields better survival than Vinorelbine (V) alone in elderly Non-Small Cell Lung Cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Group (SICOG) phase III trial. Proceedings of the American Society of Clinical Oncology 2000; 19: 485a

    Google Scholar 

  36. Dajczman E, Fu LY, Small D, et al. Treatment of small cell lung carcinoma in the elderly. Cancer 1996; 77(10): 2032–8

    Article  PubMed  CAS  Google Scholar 

  37. Goss G, Logan D, Maroun J, et al. Chemotherapy in elderly patients with Small Cell Lung Cancer (SCLC). Proceedings of the American Society of Clinical Oncology 1992; 11: 290

    Google Scholar 

  38. Smit EF, Carney DN, Harford P, et al. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989; 44(8): 631–3

    Article  PubMed  CAS  Google Scholar 

  39. Carney DN, Grogan L, Smit EF, et al. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 171 Suppl. 2: 49–53

    PubMed  CAS  Google Scholar 

  40. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995; 18(2): 149–55

    Article  PubMed  CAS  Google Scholar 

  41. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy [see comments]. J Natl Cancer Inst 1997; 89(8): 577–80

    Article  PubMed  CAS  Google Scholar 

  42. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party [see comments]. Lancet 1996; 348(9027): 563–6

    Article  PubMed  CAS  Google Scholar 

  43. Monfardini S, Balducci L. A Comprehensive Geriatric Assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur J Cancer 1999; 35(13): 1771–2

    Article  PubMed  CAS  Google Scholar 

  44. Lawton P. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988; 24(4): 609–14

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Alan Sandler is a consultant for Eli Lilly and Bristol-Myers Squibb, with research funding also being received from these two pharmaceutical companies.

Author information

Authors and Affiliations

  1. Indiana University School of Medicine, Indianapolis, Indiana, USA

    Stuart Hinton

  2. Vanderbilt University, 777 Preston Research Building, Nashville, 37232, USA

    Alan Sandler

Authors
  1. Stuart Hinton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Sandler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hinton, S., Sandler, A. Lung Cancer in the Elderly. Drugs Aging 19, 365–375 (2002). https://doi.org/10.2165/00002512-200219050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219050-00005

Keywords

Search

Navigation